Byfield J E, Zerubavel R, Fonkalsrud E W
Division of Radiation Oncology, University of California Medical School, San Diego 92093.
Cancer Immunol Immunother. 1982;14(2):117-23. doi: 10.1007/BF00200179.
The in vitro and in vivo activity has been investigated of antisera prepared against a murine (C-1300) neuroblastoma line (MNB) capable of differentiation. An antibody-dependent cellular cytotoxicity (ADCC) reaction was employed using rat spleen cells (RSC). ADCC activity in vitro (using 51Cr-release) was shown, but a maximum of only 50% of the immunologically releasable 51Cr was achieved. Nevertheless, in vivo (syngeneic mouse-tumor flank assay) significant delays were obtained in tumor onset and lethality. Under ideal circumstances, i.e., coating of tumor cells prior to inoculation and high RSC effector cell ratios, a significant number of animals could be cured of substantial tumor burdens (10(6) cells). While close proximity of the site of injection of effector cells was required (ectopic injections of RSC were ineffective), the anti-MNB ADCC was shown to be quite active in vivo without external precoating of the cells with antisera. RCS obtained from BCG-treated rats were more numerous and slightly more effective. RSC obtained from gamma-radiated animals retained normal activity. With appropriate antisera this approach could be useful under selected clinical circumstances.
已对针对一种能够分化的小鼠（C - 1300）神经母细胞瘤系（MNB）制备的抗血清的体外和体内活性进行了研究。使用大鼠脾细胞（RSC）进行抗体依赖性细胞毒性（ADCC）反应。体外ADCC活性（使用51Cr释放法）得到了证实，但最多仅达到免疫可释放的51Cr的50%。然而，在体内（同基因小鼠 - 肿瘤侧翼试验），肿瘤发生和致死率出现了显著延迟。在理想情况下，即接种前对肿瘤细胞进行包被以及高RSC效应细胞比例时，大量携带大量肿瘤负荷（10(6)个细胞）的动物可以被治愈。虽然效应细胞注射部位需要紧密相邻（RSC的异位注射无效），但抗MNB ADCC在体内表现出相当活跃，无需事先用抗血清对细胞进行体外包被。从卡介苗处理的大鼠获得的RSC数量更多且效果稍好。从γ射线照射的动物获得的RSC保留了正常活性。在选定的临床情况下，使用合适的抗血清这种方法可能会有用。
